Thomas Langenickel

Dr. Langenickel is Chief Medical Officer at Ethris. Prior to his current role, Dr. Langenickel gained two decades of pharmaceutical industry experience in drug discovery, translational medicine and clinical drug development including regulatory submissions in respiratory, cardiovascular, and metabolic diseases, resulting in three marketed medicines for the treatment of heart failure and asthma. Dr. Langenickel obtained his M.D. and Ph.D. from the Humboldt University of Berlin, Germany, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the Max-Delbrück Center for Molecular Medicine and the Charité in Berlin, Germany, and completed a post-doctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH, USA.